17,261 trials
Bipolar Disorder
Primary: Mean Scores in Children's Depression Rating Scale (CDRS-R), Assessed Before and After 6 Week Uridine Treatment — 60.00; 21.29; 33.83; 20 Units on a scale
Parkinson's Disease
Primary: Cmax - Observed Maximum Concentration — 1484; 1446; 1753; 1832 ng/mL
Cervical Cancer · Radiation Toxicity
Primary: Rate of Acute Grade 3/4 Toxicity (Excluding Grade 3 Leukopenia) — 81 percentage of participants
Recurrent Non-small Cell Lung Cancer · Stage IIIB Non-small Cell Lung Cancer · Stage IV Non-small Cell Lung Cancer
Primary: Objective Response Rate (CR or PR) According to RECIST Criteria — 5 percentage of patients responding
B-ALL
Primary: Percentage of Participants With a Best Response of Complete Remission or Complete Remission With Only Partial Hematological Recovery Within 2 Cycles of Treatment — 71.4…
Prostate Cancer · Prostatic Neoplasm
Primary: Percentage of Participants With Greater Than or Equal to (>=) 50 Percent (%) Reduction in Prostate-Specific Antigen (PSA) During the Core Study — 86.9 Percentage of…
Acute Lymphoblastic Leukemia
Primary: Percentage of Participants With a Minimal Residual Disease (MRD) Response Within 4 Cycles of Treatment — 80.0 percentage of participants — p=0.0000
Ovarian Cancer · Basal Cell Carcinoma · Metastatic Colorectal Cancer
Primary: Incidence of Participants Who Experienced at Least One Adverse Event — 17 Participants
Adult Acute Megakaryoblastic Leukemia (M7) · Adult Acute Minimally Differentiated Myeloid Leukemia (M0) · Adult Acute Monoblastic Leukemia (M5a)
Primary: Number of Participants With a Response of CR, CRp, or PR — 0; 1; 0 participants
Chronic Hepatitis C Infection · Chronic Hepatitis C
Primary: Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment — 97.4 Percentage of participants
Chronic Hepatitis C · Hepatitis C (HCV) · Hepatitis C Genotype 1
Primary: Number of Participants With Adverse Events (AEs) — 67; 36; 71; 68 participants
Obesity
Primary: Response to Food Related Cues Using Functional Magnetic Resonance Imaging - Superior Frontal — -0.35; 0.34 percent activation
Chronic Myelogenous Leukemia · Acute Myelogenous Leukemia · Chronic Lymphocytic Leukemia
Primary: Survival and Non-relapse Mortality at Day +200 Using the Miltenyi Reagent System — 43; 4 participants
Primary Open Angle Glaucoma
Primary: Mean Intra Ocular Pressure (IOP) at 8.00am — 16.6; 16.3; 17; 15.7 mmHg
Wheelchair Users
Primary: Number of Participants Reported the Endeavor to be the Same as Their Current w/c or Better With Regards to Transporting in a Vehicle — 10 participants